These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34478628)

  • 1. Human inducible pluripotent stem cells: Realization of initial promise in drug discovery.
    Kleiman RJ; Engle SJ
    Cell Stem Cell; 2021 Sep; 28(9):1507-1515. PubMed ID: 34478628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induced pluripotent stem cells: at the heart of cardiovascular precision medicine.
    Chen IY; Matsa E; Wu JC
    Nat Rev Cardiol; 2016 Jun; 13(6):333-49. PubMed ID: 27009425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrigel Mattress: A Method for the Generation of Single Contracting Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Feaster TK; Cadar AG; Wang L; Williams CH; Chun YW; Hempel JE; Bloodworth N; Merryman WD; Lim CC; Wu JC; Knollmann BC; Hong CC
    Circ Res; 2015 Dec; 117(12):995-1000. PubMed ID: 26429802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilizing microphysiological systems and induced pluripotent stem cells for disease modeling: a case study for blood brain barrier research in a pharmaceutical setting.
    Fabre KM; Delsing L; Hicks R; Colclough N; Crowther DC; Ewart L
    Adv Drug Deliv Rev; 2019 Feb; 140():129-135. PubMed ID: 30253201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells.
    Takeda M; Miyagawa S; Fukushima S; Saito A; Ito E; Harada A; Matsuura R; Iseoka H; Sougawa N; Mochizuki-Oda N; Matsusaki M; Akashi M; Sawa Y
    Tissue Eng Part C Methods; 2018 Jan; 24(1):56-67. PubMed ID: 28967302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Evolution of Stem Cells, Disease Modeling, and Drug Discovery for Neurological Disorders.
    Pernia C; Tobe BTD; O'Donnell R; Snyder EY
    Stem Cells Dev; 2020 Sep; 29(17):1131-1141. PubMed ID: 32024446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human pluripotent stem cells as tools for neurodegenerative and neurodevelopmental disease modeling and drug discovery.
    Corti S; Faravelli I; Cardano M; Conti L
    Expert Opin Drug Discov; 2015 Jun; 10(6):615-29. PubMed ID: 25891144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induced pluripotent stem cells: opportunities as research and development tools in 21st century drug discovery.
    Rowntree RK; McNeish JD
    Regen Med; 2010 Jul; 5(4):557-68. PubMed ID: 20632859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte (hiPSC-CM) Multielectrode Array Assay for Preclinical Cardiac Electrophysiology Safety Screening.
    Harris K
    Curr Protoc Pharmacol; 2015 Dec; 71():11.18.1-11.18.15. PubMed ID: 26646193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of human induced pluripotent stem cells in metabolic disorders: from drug discovery toward precision medicine.
    Cota-Coronado A; Ramírez-Rodríguez PB; Padilla-Camberos E; Díaz ÉF; Flores-Fernández JM; Ávila-Gónzalez D; Diaz-Martinez NE
    Drug Discov Today; 2019 Jan; 24(1):334-341. PubMed ID: 30292915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advancing physiological maturation in human induced pluripotent stem cell-derived cardiac muscle by gene editing an inducible adult troponin isoform switch.
    Wheelwright M; Mikkila J; Bedada FB; Mandegar MA; Thompson BR; Metzger JM
    Stem Cells; 2020 Oct; 38(10):1254-1266. PubMed ID: 32497296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiotoxicity evaluation using human embryonic stem cells and induced pluripotent stem cell-derived cardiomyocytes.
    Zhao Q; Wang X; Wang S; Song Z; Wang J; Ma J
    Stem Cell Res Ther; 2017 Mar; 8(1):54. PubMed ID: 28279214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploiting pluripotent stem cell technology for drug discovery, screening, safety, and toxicology assessments.
    McGivern JV; Ebert AD
    Adv Drug Deliv Rev; 2014 Apr; 69-70():170-8. PubMed ID: 24309014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease modelling and drug discovery for hypertrophic cardiomyopathy using pluripotent stem cells: how far have we come?
    Lam CK; Wu JC
    Eur Heart J; 2018 Nov; 39(43):3893-3895. PubMed ID: 30010924
    [No Abstract]   [Full Text] [Related]  

  • 15. hiPSC-CM Monolayer Maturation State Determines Drug Responsiveness in High Throughput Pro-Arrhythmia Screen.
    da Rocha AM; Campbell K; Mironov S; Jiang J; Mundada L; Guerrero-Serna G; Jalife J; Herron TJ
    Sci Rep; 2017 Oct; 7(1):13834. PubMed ID: 29061979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human pluripotent stem cell models of cardiac disease: from mechanisms to therapies.
    Brandão KO; Tabel VA; Atsma DE; Mummery CL; Davis RP
    Dis Model Mech; 2017 Sep; 10(9):1039-1059. PubMed ID: 28883014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human pluripotent stem cell-derived cardiomyocyte based models for cardiotoxicity and drug discovery.
    Zhao Y; Korolj A; Feric N; Radisic M
    Expert Opin Drug Saf; 2016 Nov; 15(11):1455-1458. PubMed ID: 27560951
    [No Abstract]   [Full Text] [Related]  

  • 18. Perspectives and Challenges of Pluripotent Stem Cells in Cardiac Arrhythmia Research.
    Goedel A; My I; Sinnecker D; Moretti A
    Curr Cardiol Rep; 2017 Mar; 19(3):23. PubMed ID: 28220464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.
    Sharma A; Burridge PW; McKeithan WL; Serrano R; Shukla P; Sayed N; Churko JM; Kitani T; Wu H; Holmström A; Matsa E; Zhang Y; Kumar A; Fan AC; Del Álamo JC; Wu SM; Moslehi JJ; Mercola M; Wu JC
    Sci Transl Med; 2017 Feb; 9(377):. PubMed ID: 28202772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human-induced pluripotent stem cell-derived cardiomyocytes from cardiac progenitor cells: effects of selective ion channel blockade.
    Altomare C; Pianezzi E; Cervio E; Bolis S; Biemmi V; Benzoni P; Camici GG; Moccetti T; Barile L; Vassalli G
    Europace; 2016 Dec; 18(suppl 4):iv67-iv76. PubMed ID: 28011833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.